secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001847367-25-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis Q2 net income $59.3M (incl. $187.9M merger gain); Phase 3 psoriasis & Phase 2b SLE enrollment complete
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.
- Phase 3 ONWARD trials (psoriasis) fully enrolled; topline data expected early Q1 2026.
- Phase 2b LUMUS trial (SLE) fully enrolled with 408 patients; topline data expected Q3 2026.
- Completed merger with ACELYRIN, adding $382.6M cash; total merger-related expenses of $26.8M in Q2.
- R&D expenses $108.8M (up from $48.6M); G&A $34.5M (up from $7.6M) driven by merger costs and clinical acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/0001847367-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001847367-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer